Morongwe Likoti

Adjunctive host-directed therapies for pulmonary tuberculosis: a prospective, open-label, phase 2, randomised controlled trial

Robert S. Wallis, Sibuse Ginindza, Trevor Beattie et al. · The Lancet Respiratory Medicine · 2021 · 131 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +13

Once-weekly rifapentine and isoniazid for tuberculosis prevention in patients with HIV taking dolutegravir-based antiretroviral therapy: a phase 1/2 trial

Kelly E. Dooley, Radojkam Savic, Akshay Gupte et al. · The Lancet HIV · 2020 · 66 citations

Public Health, Pharmacology, Pharmacotherapy +14

Failure of A Novel, Rapid Antigen and Antibody Combination Test to Detect Antigen-Positive HIV Infection in African Adults with Early HIV Infection

William Kilembe, Michelle Keeling, Etienne Karita et al. · PLoS ONE · 2012 · 37 citations · Full text

Public Health, Immunology, Infectious Diseases +16

Lung and blood early biomarkers for host-directed tuberculosis therapies: Secondary outcome measures from a randomized controlled trial

Robert S. Wallis, Sibuse Ginindza, Trevor Beattie et al. · PLoS ONE · 2022 · 17 citations · Full text

Veterinary Medicine, Clinical Sciences, Infectious Diseases +16